超声造影联合血清lncRNA PCAT6检测对乳腺癌的诊断价值

常新; 汪金; 韩春荣; 万珂

doi:10.13898/j.cnki.issn.2097-5252.2025.03.021

超声造影联合血清lncRNA PCAT6检测对乳腺癌的诊断价值

Value of contrast-enhanced ultrasound combined with serum lncRNA PCAT6 detection in the diagnosis of breast cancer

摘要

摘要: 目的： 探讨超声造影联合血清长链非编码RNA(lncRNA)前列腺相关转录本6(PCAT6)检测对乳腺癌的诊断价值。方法： 选取72例乳腺癌病人作为乳腺癌组，68例乳腺良性疾病病人作为乳腺良性疾病组。所有受试者均进行超声造影检查及血清lncRNA PCAT6、糖类抗原153(CA153)水平检测。分析超声造影检查、血清lncRNA PCAT6、CA153诊断乳腺癌的价值。结果： 乳腺癌组病人高增强占比、增强后病灶增大占比均明显高于乳腺良性疾病组(P<0.01)。超声造影诊断乳腺癌的灵敏度为73.61%，特异度为89.71%，准确度为81.43%。乳腺癌组病人血清lncRNA PCAT6、CA153水平均明显高于乳腺良性疾病组(P<0.01)。血清lncRNA PCAT6、CA153诊断乳腺癌的AUC分别为0.882、0.719，截断值分别为1.56、27.28 U/mL，灵敏度分别为76.39%、61.11%，特异度分别为88.24%、82.35%，准确度分别为82.14%、71.43%。超声造影检查联合血清lncRNA PCAT6诊断乳腺癌的灵敏度为98.61%，特异度为86.76%，准确度为92.86%。结论： 超声造影检查联合血清lncRNA PCAT6检测诊断乳腺癌的价值较高，有望成为早期诊断乳腺癌的一种临床参考方案。

Abstract: Objective: To investigate the diagnostic value of contrast-enhanced ultrasound combined with serum long non-coding RNA(lncRNA) prostate cancer-associated transcript 6(PCAT6) detection in breast cancer. Methods: A total of 72 patients with breast cancer were selected as breast cancer group,and 68 patients with benign breast diseases were selected as breast benign disease group.The contrast-enhanced ultrasound were performed in two groups,and the serum levels of lncRNA PCAT6 and carbohydrate antigen 153(CA153) levels were detected.The value of contrast-enhanced ultrasound and serum levels of lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were analyzed. Results: The proportions of high enhancement and lesion enlargement in breast cancer group were significanthy higher than those in benign breast disease group(P<0.01).The sensitivity,specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of breast cancer were 73.61%,89.71% and 81.43%,respectively.The serum levels of lncRNA PCAT6 and CA153 in the breast cancer group were significantly higher than those in benign breast disease group(P<0.01).The AUC,cut-off value,sensitivity,specificity and accuracy of serum lncRNA PCAT6 and CA153 in the diagnosis of breast cancer were (0.882 and 0.719),(1.56 and 27.28 U/mL),(76.39% and 61.11%).The sensitivity,specificity and accuracy of contrast-enhanced ultrasound combined with serum lncRNA PCAT6 in the diagnosis of breast cancer were 98.61%,86.76% and 92.86%,respectively. Conclusions: The contrast-enhanced ultrasound combined with serum lncRNA PCAT6 detection has high value in the diagnosis of breast cancer,and it is expected to become a clinical reference scheme for early diagnosis of breast cancer.

HTML全文

参考文献(23)

施引文献

资源附件(0)